Press Release – medac at the BAD meeting 2017

Update on the first-line agent Methotrexate in psoriasis treatment: Intensified dosing and subcutaneous administration recommended

British Association of Dermatologists’ guidelines reaffirms the importance of the well- established and inexpensive first-line systemic agent Methotrexate (MTX) for the treatment of patients with all types of psoriasis
Recently in The Lancet published METOP trial meets the need of high-quality clinical trial with methotrexate in long-term therapy and shows lasting efficacy and safety of subcutaneous methotrexate over one year in an intensified dosing schedule